Clinical Genomics Laboratory

Publications

Found 16 results
Author Title [ Type(Asc)] Year
Filters: First Letter Of Last Name is K  [Clear All Filters]
Journal Article
Kluk MJ, R Lindsley C, Aster JC, Lindeman NI, Szeto D, Hall D, Kuo FC.  2016.  Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies.. J Mol Diagn. 18(4):507-15.
Kluk MJ, R Lindsley C, Aster JC, Lindeman NI, Szeto D, Hall D, Kuo FC.  2016.  Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies.. J Mol Diagn. 18(4):507-15.
Saab J, Zia H, Mathew S, Kluk M, Narula N, Fernandes H.  2017.  Utility of Genomic Analysis in Differentiating Synchronous and Metachronous Lung Adenocarcinomas from Primary Adenocarcinomas with Intrapulmonary Metastasis.. Transl Oncol. 10(3):442-449.
Nam AS, Kim K-T, Chaligne R, Izzo F, Ang C, Taylor J, Myers RM, Abu-Zeinah G, Brand R, Omans ND et al..  2019.  Somatic mutations and cell identity linked by Genotyping of Transcriptomes.. Nature. 571(7765):355-360.
Shanmugam V, Margolskee E, Kluk M, Giorgadze T, Orazi A.  2016.  Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation.. Head Neck Pathol. 10(3):394-9.
Kluk MJ, Abo RP, Brown RD, Kuo FC, Dal Cin P, Pozdnyakova O, Morgan EA, Lindeman NI, DeAngelo DJ, Aster JC.  2015.  Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom next-generation sequencing assay.. Cold Spring Harb Mol Case Stud. 1(1):a000307.
Kluk MJ, Abo RP, Brown RD, Kuo FC, Dal Cin P, Pozdnyakova O, Morgan EA, Lindeman NI, DeAngelo DJ, Aster JC.  2015.  Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom next-generation sequencing assay.. Cold Spring Harb Mol Case Stud. 1(1):a000307.
Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3
Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3
Rosenbaum JN, Bloom R, Forys JT, Hiken J, Armstrong JR, Branson J, McNulty S, Velu PD, Pepin K, Abel H et al..  2018.  Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.. Mod Pathol. 31(5):791-808.
Rosenbaum JN, Bloom R, Forys JT, Hiken J, Armstrong JR, Branson J, McNulty S, Velu PD, Pepin K, Abel H et al..  2018.  Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.. Mod Pathol. 31(5):791-808.
Kluk MJ, Bagg A.  2019.  Expedited Analysis and Reporting of Multiple Mutations that Modify Medical Management of Myeloid Malignancies: It's About (Turnaround) Time!. J Mol Diagn. 21(1):13-15.
Rennert H, Eng K, Zhang T, Tan A, Xiang J, Romanel A, Kim R, Tam W, Liu Y-C, Bhinder B et al..  2016.  Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care.. NPJ Genom Med. 1
Rennert H, Eng K, Zhang T, Tan A, Xiang J, Romanel A, Kim R, Tam W, Liu Y-C, Bhinder B et al..  2016.  Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care.. NPJ Genom Med. 1
Khorrami M, Prasanna P, Gupta A, Patil P, Velu PD, Thawani R, Corredor G, Alilou M, Bera K, Fu P et al..  2020.  Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer.. Cancer Immunol Res. 8(1):108-119.
Huang L, Fernandes H, Zia H, Tavassoli P, Rennert H, Pisapia D, Imielinski M, Sboner A, Rubin MA, Kluk M et al..  2017.  The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations.. J Am Med Inform Assoc. 24(3):513-519.